LCM
ZYME icon

Lynwood Capital Management’s Zymeworks ZYME Stock Holding History

Lynwood Capital Management’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-300,000
Closed -$1.59M – 157
2022
Q2 		$1.59M Buy
+300,000
New +$1.81M 1.78% 14

Other funds holding ZYME

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Lynwood Capital Management's ZYME Position: Q3 2022 in Review

Lynwood Capital Management sold out of Zymeworks (ZYME) in Q3 2022, closing a stake of 300,000 shares — an estimated $1.59M sold.

Lynwood Capital Management first reported a position in ZYME in Q2 2022 and held it in 1 quarter. The position peaked at $1.59M in Q2 2022. 91 funds tracked by Wall St. Rank hold ZYME as of Q3 2022.

  • Lynwood Capital Management reported no remaining Zymeworks position as of Q3 2022 after selling out during the quarter.
  • Lynwood Capital Management sold 300,000 Zymeworks shares in Q3 2022, an estimated $1.59M.
  • Lynwood Capital Management first reported a position in Zymeworks in Q2 2022 and held it in 1 quarter.
  • Lynwood Capital Management's Zymeworks position peaked at $1.59M in Q2 2022.
  • 91 funds tracked by Wall St. Rank held Zymeworks as of Q3 2022.

Based on Lynwood Capital Management's 13F filing for Q3 2022, filed 25 Oct 2022.